EGFR inhibitors used in clinical trials for the treatment of advanced cSCC only have modest clinical benefit, with 25–45% of the patients achieving partial responses and 0–18% obtaining complete remission [52]. The gene discussed is EGFR; the disease is skin squamous cell carcinoma.